People are increasingly interested in microdosing GLP-1 medications because even at the lowest therapeutic doses, these medications appear to influence multiple metabolic pathways
GIP (Glucose-dependent insulinotropic polypeptide): This hormone helps lower blood sugar levels, particularly after eating, and contributes to improved fat metabolism helping the body process and store fat more efficiently
Given the relatively high level of gross Medicare Part D spending as of 2022 for the two semaglutide products combined, Ozempic and Rybelsus, its possible that Medicare could select this product for drug price negotiation as early as 2025, which would be just over seven years past its earliest FDA approval in late 2017
The packaging conclusion GLP-1 drugs are often framed as a pharmaceutical breakthrough
Liver function: Research has shown that semaglutide results in improved liver fat and scarring, and MASH (which stands for metabolic dysfunction-associated steatohepatitis) is an FDA-approved indication
Food loses its pull, making it easier to break cycles of emotional eating